SCHEMBL320837

SCHEMBL320837

COC(=O)c1cccc(-c2c(C)c(C(=O)c3ccc4nc(C)[nH]c(=O)c4c3)n3ccccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
TNKS O95271 1/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 2/20 0.39
PPARG P37231 2/20 0.39
NCOR2 Q9Y618 2/20 0.39
PABPC1 P11940 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PTGER4 P35408 1/20 0.38
LMNA P02545 2/20 0.37
NEK1 Q96PY6 1/20 0.37
AXL P30530 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320647 0.92 ALDH1A1 (0.41) MAPTALDH1A1KMT2AKDM4EPOLB
SCHEMBL321154 0.82 LMNA (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL320304 0.80 ALDH1A1 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL320893 0.77 MAPT (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL27922041 0.76 PDE5A (0.41) MAPTALDH1A1KMT2AKDM4EPOLB
SCHEMBL27904274 0.72 MAPT (0.44) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13918696 0.71 MAPT (0.53) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL321326 0.71 MAPT (0.40) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL27758529 0.70 MAPT (0.45) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL320396 0.69 ALDH1A1 (0.43) MAPTALDH1A1KDM4EPPARGHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 MAPT 961/4885TNKS 133/4885ALDH1A1 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.